 |
|
Relapse of Tuberculosis After Treatment in Human Immunodeficiency Virus—Infected Patients
Federico Pulido, MD;
Jose-Maria Peña, MD;
Rafael Rubio, MD;
Santiago Moreno, MD;
Juan González, MD;
Carlos Guijarro, MD;
Jose-Ramón Costa, MD;
Juan-José Vázquez, MD
Arch Intern Med. 1997;157(2):227-232.
Abstract
| |
Objectives
To evaluate the relapse rate of tuberculosis after a complete course of antituberculous therapy in human immunodeficiency virus—infected patients and to identify the risk factors for relapse.
Patients and Methods
Historic cohort study of all adult patients who were diagnosed as having human immunodeficiency virus infection and a first episode of culture-proved tuberculosis at 2 university hospitals in Madrid, Spain, between 1986 and 1992, and who completed at least 6 months of treatment were included and followed up until September 1994.
Results
Of 276 patients with human immunodeficiency virus infection and tuberculosis, 87 could not be evaluated (6 died before treatment, 39 died during treatment, 36 did not complete the planned therapy, and 6 were unavailable during treatment). The remaining 189 received a standard regimen (ie, 3 or 4 drugs, always including rifampin and isoniazid, for  6 months). The median duration of follow-up for these 189 patients was 31.5 months, with a total of 4668 patient-months of follow-up after treatment; 105 patients (56%) were followed up until death. The relapse rate was 7.9% (2.7/ 100 patient-years). With multivariate analysis, a shorter duration of treatment and a low CD4+ cell count were associated with a greater probability of relapse. Relapses occurred in 5 (3.4%) of 148 patients who were treated for 9 or more months (1.7/100 patient-years) and in 10 (24%) of 41 patients who were treated for less than 9 months (10.9/100 patient-years) (P<.001; relative hazard, 9.2; 95% confidence interval, 3.1-26.9).
Conclusions
As standard antituberculous therapy for 9 months is associated with a low rate of relapse, maintenance therapy is not required. Duration of treatment for less than 9 months is associated with a high rate of relapse.
Arch Intern Med. 1997;157:227-232
Author Affiliations
From the Unidades VIH, Servicios de Medicina Interna, Hospital 12 de Octubre (Drs Pulido, Rubio, Guijarro, and Costa) and Hospital La Paz (Drs Peña, González, and Vázquez), Madrid, Spain, and the Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital Morales Meseguer, Murcia, Spain (Dr Moreno).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Epidemiology of Venous Thromboembolism in the Community
Heit
Arterioscler. Thromb. Vasc. Bio. 2008;28:370-372.
FULL TEXT
Thrombophilia: Common Questions on Laboratory Assessment and Management
Heit
ASH Education Book 2007;2007:127-135.
ABSTRACT
| FULL TEXT
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen
Lopez-Cortes et al.
J Antimicrob Chemother 2006;58:1017-1023.
ABSTRACT
| FULL TEXT
Current medical treatment for tuberculosis
Chan and Iseman
BMJ 2002;325:1282-1286.
FULL TEXT
Molecular Epidemiology Study of Exogenous Reinfection in an Area with a Low Incidence of Tuberculosis
Bandera et al.
J. Clin. Microbiol. 2001;39:2213-2218.
ABSTRACT
| FULL TEXT
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
Havlir and Barnes
NEJM 1999;340:367-373.
FULL TEXT
How Long Should TB Treatment Last?
AIDS Clin Care 1997;1997:6-6.
FULL TEXT
|
